Publications by authors named "Concetta Ferracane"

Claim this Profile
C
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study.
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Clara De Francesco, Nunzio Belluardo, Concetta Ferracane

Dig Liver Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Maria Cappello, Piera Melatti, Concetta Ferracane

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
Tommaso Innocenti, Jurij Hanžel, Marie Truyens, Milan Lukaš, Hannah Gordon, Concetta Ferracane

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
Fabio Salvatore Macaluso, Mauro Grova, Fabrizio Bossa, Sonia Carparelli, Daniela Pugliese, Concetta Ferracane

Therap Adv Gastroenterol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases.
Fabio Salvatore Macaluso, Sara Renna, Walter Fries, Anna Viola, Maria Cappello, Concetta Ferracane

Inflamm Bowel Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.
Fabio Salvatore Macaluso, Elvira D'Antonio, Walter Fries, Anna Viola, Omar Ksissa, Concetta Ferracane

Dig Liver Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Fabio Salvatore Macaluso, Mauro Grova, Filippo Mocciaro, Roberto Di Mitri, Antonino Carlo Privitera, Concetta Ferracane

J Gastroenterol Hepatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, Anna Viola, Alfredo Abbruzzese, Concetta Ferracane

Inflamm Bowel Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease.
Fabio Salvatore Macaluso, Maria Cappello, Federica Crispino, Mauro Grova, Antonino Carlo Privitera, Concetta Ferracane

Dig Liver Dis· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
Fabio Salvatore Macaluso, Maria Cappello, Anita Busacca, Walter Fries, Anna Viola, Concetta Ferracane

J Gastroenterol Hepatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases.
Anna Viola, Marco Muscianisi, Fabio S Macaluso, Marco Ventimiglia, Maria Cappello, Concetta Ferracane

JGH Open· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
Fabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, Anna Viola, Maria Cappello, Concetta Ferracane

Dig Liver Dis· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Giuseppe Costantino, Marco Muscianisi, Concetta Ferracane

Expert Opin Biol Ther· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis.
Fabrizio Bossa, Giuseppe Biscaglia, Maria Rosa Valvano, Giuseppe Costantino, Angelo Lauria, Concetta Ferracane

Dig Dis Sci· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Serena Porcari, Anna Viola, Ambrogio Orlando, Antonino Carlo Privitera, Concetta Ferracane

Drugs Aging· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
Fabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, Maria Cappello, Sebastiano Siringo, Concetta Ferracane

J Crohns Colitis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Sara Renna, Filippo Mocciaro, Marco Ventimiglia, Rosalba Orlando, Fabio Salvatore Macaluso, Concetta Ferracane

Dig Liver Dis· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Fabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, Mariangela Scolaro, Antonio Magnano, Concetta Ferracane

Dig Liver Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis